e-Therapeutics plc Director Dealing and Issue of Equity (2832R)
05 Julio 2022 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 2832R
e-Therapeutics plc
05 July 2022
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
DIRECTOR DEALING AND ISSUE OF EQUITY
London, UK, 5 July 2022 - e-therapeutics plc (AIM: ETX), the
drug discovery company, announces that o n 4 July 2022, Professor
Trevor Jones (Non-Executive Chairman of the Company) subscribed for
a total of 43,913 new ordinary shares of 0.1p each in the Company
(the "New Ordinary Shares") a t a price of 17.22 pence per share.
The subscription monies paid for the New Ordinary Shares represent
50% of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 January 2022 to 30 June 2022 in accordance
with the agreement entered into with Professor Jones, previously
announced o n 5 October 2016, by which Professor Jones agreed, with
effect from 1 October 2016, to invest 50% of his annual
Non-Executive Director fees net of tax in new e-therapeutics'
ordinary shares. Such new shares are issued to Professor Jones on
the first business day after 31 December and 30 June in each year.
The subscription price to be paid is the average of the closing
mid-market price for the five business days prior to the date of
issue.
Following Admission, Professor Jones will be interested in a
total of 1,123,391 ordinary shares of 0.1p in the Company,
representing approximately 0.22% of the Company's issued share
capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 11 July 2022. The New
Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 514,614,982. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Trevor Jones
---------------------------- -----------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------
a) Position/status Non-Executive Chairman
---------------------------- -----------------------------------------
b) Initial notification/ Initial notification
Amendment
---------------------------- -----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name e-therapeutics plc
---------------------------- -----------------------------------------
b) LEI 21380049RHSSJXWKYT18
---------------------------- -----------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
---------------------------- -----------------------------------------
b) Nature of the transaction Purchase of shares
---------------------------- -----------------------------------------
c) Price(s) and volume(s) 4 3,913 ordinary shares at a price of 1
7.22 pence per share
---------------------------- -----------------------------------------
d) Aggregated information 4 3,913 ordinary shares
- Aggregated volume 1 7.22 pence per share
- Price Aggregated value: GBP7,561.8 2
---------------------------- -----------------------------------------
e) Date of the transaction 4 July 2022
---------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -----------------------------------------
For further information, please contact:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993
Laura Roca-Alonso, CBO 883 125
www.etherapeutics.co.uk
SP Angel Corporate Finance LLP
Nominated Adviser and Broker Tel: +44(0)20 3470
0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is a UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e- therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV, iTeos and a
US-based, top 5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFADVISIIF
(END) Dow Jones Newswires
July 05, 2022 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024